ESC Guideline on the Management of STEMI Recommendation for DAPT

Slides:

Advertisements

Similar presentations

Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.

Advertisements

Management of ST-elevation myocardial infarction according to European and American guidelines.

Pharmacotherapy in acute coronary syndromes Perspective from first line and regional hospitals in Czech Republic Cardionale, Petr Jansky.

Meta Analysis of Primary PCI trials Andreas Baumbach*, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran,

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.

Canadian Cardiovascular Society Antiplatelet Guidelines

Heparin Should be the First-line Therapy for Patients with ACS/AMI

Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.

Randomisation before planned PCI with DES (n=2500)

European and US Guidelines

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Preventing Thrombotic Complications in ACS: State of the Art

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Anticoagulants in Interventional Cardiology:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Emerging Data on ACS Management From ACC

Applying New Data in Practice:

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Selecting NOACs for High-Risk Patients

Tailoring Antiplatelet Therapy in PCI

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Heart Failure Prevention: Mission Impossible?

The Essentials for Secondary Stroke Prevention

Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

Treatment Options to Consider

New Pathways in Lipid Care

Program Overview. Treatment Options for Post-MI patients with LVD – are all ACE Inhibitors Equal?

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

Learning Objectives Classification of VTE Goals of VTE Treatment.

Thank you for taking the pre-assessment

Practical Considerations to Extend Treatment for VTE

The Importance of Getting the Dose Right in HF

Overview. Complex Cases in PCI: Tailoring Antiplatelet Therapy to Improve Outcomes.

TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES

Duration of Dual Antiplatelet Therapy

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Improving Adherence to Antiplatelet Therapy After an ACS Event

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges

Roberta Rossini et al. JCIN 2018;11:

TL-PAS: DAPT Trial design: Patients undergoing PCI with Taxus Liberté PES, receiving prasugrel, without ischemic/bleeding complications, and compliant.

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing

(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus.

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

Section C: Clinical trial update: Oral antiplatelet therapy

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

ESC Guideline on the Management of STEMI Recommendation for DAPT

2013 ACCF/AHA Guideline for the Management of STEMI

TRANSLATE-ACS

TRANSLATE-ACS Antiplatelet Use After PCI

TRANSLATE-ACS Prasugrel vs Clopidogrel

ACTION Registry®-GWTG™ Factors Associated With In-hospital Bleeding

Treatment Paradox Use of More Potent Antiplatelet Agents

TRANSLATE-ACS Gender Differences in Outcomes

TRANSLATE-POPS Design

TRANSLATE-POPS Platelet Testing in the US Resulting in Change in Therapy

TRANSLATE-POPS 30-day Outcomes

Platelet Function Testing Scenarios for Use

An Illustrative Case

Key Variables to Consider

CURRENT-OASIS 7 High-dose vs Low-dose Aspirin

Abbreviations

Abbreviations (cont)

References

References (cont)